Aurinia Pharmaceuticals Inc. announced that Mr. Peter Greenleaf, Chief Executive Officer, will present a corporate overview at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 22, 2019 at 6:30am PT (9:30am ET) in New York, NY.
VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “Company”) today announced that Mr. Peter Greenleaf, Chief Executive Officer, will present a corporate overview at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 22, 2019 at 6:30am PT (9:30am ET) in New York, NY.
The presentation will be webcast live and can be accessed via the investor section of the Aurinia website, www.auriniapharma.com. A replay of the presentation will also be archived on the Company website following the event.
About Aurinia
Aurinia Pharmaceuticals Inc. is a late clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations impacted by serious diseases with a high unmet medical need. The company is currently developing voclosporin, an investigational drug, for the potential treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and dry eye syndrome (DES). The company is headquartered in Victoria, British Columbia and focuses its development efforts globally. For further information, see our website at www.auriniapharma.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190517005433/en/
Contacts
Investor Contact:
Glenn Schulman, PharmD, MPH
Corporate Communications
gschulman@auriniapharma.com
or
Media Contact:
Christopher Hippolyte
212-364-0458
Christopher.Hippolyte@inventivhealth.com
Source: Aurinia Pharmaceuticals Inc.
View this news release online at:
http://www.businesswire.com/news/home/20190517005433/en
